Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

NCT07222800 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07222800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07222800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
December 11, 2025
Completion date
August 17, 2031
Enrollment
800 (estimated)
Sites
372

Conditions

As the registry lists them; a condition with its own page is linked.

colonic diseases, colorectal neoplasms, digestive system diseases, digestive system neoplasms, gastrointestinal diseases, gastrointestinal neoplasms, intestinal diseases, intestinal neoplasms, neoplasms by site, rectal diseases